A detailed history of Raymond James & Associates transactions in Cassava Sciences Inc stock. As of the latest transaction made, Raymond James & Associates holds 76,959 shares of SAVA stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,959
Previous 76,047 1.2%
Holding current value
$2.27 Million
Previous $1.54 Million 38.39%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$12.35 - $26.11 $11,263 - $23,812
912 Added 1.2%
76,959 $950,000
Q1 2024

Apr 22, 2024

BUY
$18.44 - $26.41 $35,958 - $51,499
1,950 Added 2.63%
76,047 $1.54 Million
Q4 2023

Jan 16, 2024

BUY
$12.64 - $30.11 $7,141 - $17,012
565 Added 0.77%
74,097 $1.67 Million
Q3 2023

Oct 24, 2023

BUY
$16.64 - $25.32 $201,826 - $307,106
12,129 Added 19.75%
73,532 $1.22 Million
Q2 2023

Jul 25, 2023

SELL
$21.59 - $27.88 $70,404 - $90,916
-3,261 Reduced 5.04%
61,403 $1.51 Million
Q1 2023

Apr 14, 2023

BUY
$23.46 - $36.44 $84,268 - $130,892
3,592 Added 5.88%
64,664 $1.56 Million
Q4 2022

Feb 08, 2023

BUY
$27.82 - $44.16 $66,378 - $105,365
2,386 Added 4.07%
61,072 $1.8 Million
Q3 2022

Oct 25, 2022

BUY
$16.33 - $51.06 $223,002 - $697,275
13,656 Added 30.33%
58,686 $2.45 Million
Q2 2022

Aug 12, 2022

SELL
$17.22 - $38.47 $147,695 - $329,957
-8,577 Reduced 16.0%
45,030 $1.27 Million
Q1 2022

May 11, 2022

BUY
$32.6 - $53.05 $323,261 - $526,043
9,916 Added 22.7%
53,607 $1.99 Million
Q4 2021

Feb 08, 2022

BUY
$36.77 - $90.91 $206,059 - $509,459
5,604 Added 14.71%
43,691 $1.91 Million
Q3 2021

Nov 02, 2021

BUY
$41.79 - $135.3 $833,501 - $2.7 Million
19,945 Added 109.94%
38,087 $2.36 Million
Q2 2021

Aug 11, 2021

SELL
$32.15 - $89.72 $80,021 - $223,313
-2,489 Reduced 12.06%
18,142 $1.55 Million
Q1 2021

May 14, 2021

BUY
$7.09 - $87.95 $146,273 - $1.81 Million
20,631 New
20,631 $927,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.18B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.